Literature DB >> 2754134

Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing.

D E Morgan1, C W Tomlinson, A K Qayumi, P M Toleikis, B McConville, W R Jamieson.   

Abstract

Eight dogs were studied by simultaneous invasive hemodynamic and two-dimensional echocardiographic methods to determine whether left ventricular contractility is altered by 2 weeks of rapid atrial pacing. Additionally, this study evaluated the response of three ventricular contractility indexes to both the pacing intervention and acute load alteration. The indexes compared were ejection fraction, peak systolic pressure to end-systolic volume index ratio (SBP/ESVI) and end-systolic wall stress to end-systolic volume index ratio (ESWS/ESVI). After 2 weeks of pacing at 265 +/- 20 min-1 (mean +/- SD), cardiac index and ejection fraction were reduced to 73 +/- 38 ml/kg per min and 22 +/- 6%, respectively, from 161 +/- 22 and 46 +/- 7 before pacing (both p less than 0.001). Concomitantly, SBP/ESVI and ESWS/ESVI were reduced to 34 +/- 10 mm Hg/ml per kg and 54 +/- 19 g/cm2 per ml per kg, respectively, from 84 +/- 29 and 121 +/- 36 before pacing (both p less than 0.005). There were high correlations for the changes in SBP/ESVI and ejection fraction (r = 0.94, p less than 0.001) and ESWS/ESVI and ejection fraction (r = 0.89, p less than 0.003). Acute afterload alteration with phenylephrine depressed ejection fraction but not SBP/ESVI or ESWS/ESVI. Therefore, this study demonstrates 1) that left ventricular contractility is markedly depressed in the dog by 2 weeks of rapid atrial pacing, and 2) that SBP/ESVI and ESWS/ESVI are superior to ejection fraction as ventricular contractility indexes because these ratios accurately measure contractility changes but are influenced less by after-load conditions.

Entities:  

Mesh:

Year:  1989        PMID: 2754134     DOI: 10.1016/0735-1097(89)90206-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure.

Authors:  K Komamura; R P Shannon; A Pasipoularides; T Ihara; A S Lader; T A Patrick; S P Bishop; S F Vatner
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 2.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419

Review 3.  Heart failure and tachycardia-induced cardiomyopathy.

Authors:  Ethan R Ellis; Mark E Josephson
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 4.  Animal models of dilated cardiomyopathy for translational research.

Authors:  F A Recchia; V Lionetti
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

5.  What About Tachycardia-induced Cardiomyopathy?

Authors:  Ethan R Ellis; Mark E Josephson
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11

Review 6.  Reversible Cardiomyopathies.

Authors:  Harsh Patel; Raef Madanieh; Constantine E Kosmas; Satya K Vatti; Timothy J Vittorio
Journal:  Clin Med Insights Cardiol       Date:  2015-05-21

7.  Acute Tachycardia-Induced Cardiomyopathy: A Case Report.

Authors:  Mohamed Amr
Journal:  Am J Case Rep       Date:  2021-05-10

8.  Tachycardia-Induced Cardiomyopathy in a Young Healthy Patient: A Case Report.

Authors:  Zahid Khan; George Besis; Joseph Tomson
Journal:  Cureus       Date:  2022-09-08

9.  Distinguishing Tachycardia Mediated From Structural Cardiomyopathy: Association of Late Gadolinium Enhancement With Recovery of Ventricular Systolic Function Following Atrial Fibrillation Ablation.

Authors:  Saman Nazarian
Journal:  J Am Heart Assoc       Date:  2016-09-26       Impact factor: 5.501

Review 10.  Pathophysiology, diagnosis and treatment of tachycardiomyopathy.

Authors:  Claire A Martin; Pier D Lambiase
Journal:  Heart       Date:  2017-08-30       Impact factor: 5.994

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.